GOLDENWELL BIOTECH, INC.

Goldenwell Biotech, Inc.

Overview

• Incorporated: August 20, 2019
• Fiscal year end: December 31
• Subsidiaries: None
• Headquarters / mailing address: 7316 Capilano Dr., Solon, Ohio 44139
• Operations: The company does not conduct operations; it functions primarily as a shell company that receives mail at the address.

Products and development status

The company describes five products and reports that development steps have been completed.

• Ji Mai — Bovine Cardiac Vascular Active Peptide (Polypeptide Freeze-dried Powder)

  • Vascular peptide derived from bovine tissue; produced via closed, low-temperature processing with freeze-drying; claims biocompatibility and easy human absorption.

• Double Proline AG — 3D Active Collagen Peptide (DPAG) (Drinkable Cosmetics)

  • Bioactive collagen peptide support; molecular weight ~1920 Da; produced via enzymolysis and extraction; contains no pigments or artificial additives.

• Cartilage Peptide — Type II Collagen Peptide

  • Peptide derived from bovine and porcine cartilage bones; molecular weight ~8000 Da; includes bio calcium and is positioned for dietary supplement use.

• Se Plus (Category II Solid Tablets)

  • Selenium-based antioxidant supplement; ingredients include L-Se-Methylselenocysteine (MSC) and high selenium yeast; targeted at middle-aged and elderly or selenium-deficient individuals.

• Sugar Master

  • Plant-based dietary supplement produced via low-temperature extraction to preserve bioactive compounds; includes natural plant extracts and a high-efficiency organic selenium complex; processing is described as cryogenic to preserve bitter melon components charantin and momordicoside.

Status of production and operations

• The company reports completion of initial market analysis, competitive analysis, marketing strategy, research and development activities (raw material selection, formulation, lab testing, QA/QC), and production planning steps (process optimization, equipment selection, site location, workshop setup).
• There are no current manufacturing operations. Equipment is described as obtainable from existing manufacturers. Workforce training is anticipated; the company indicates that specialized education or experience is not required for labor.

Intellectual property and licensing

• The company does not own patents.
• Intellectual property protection is based on trademarks, trade secrets, confidentiality, and contractual provisions.
• Exclusive licenses:
  1. Australian Trefoil Health Technologies Pty Ltd (effective July 20, 2020)
     • Licensed technology and packaging designs for Sugar Master and DNA Repair products and other products.
     • Territory: Worldwide excluding China.
     • Term: For the term of the underlying patent; expires November 15, 2025.
     • Consideration: $10.00.
     • Related party: Li Yang, a director of the company, controls Australian Trefoil.
  2. Ji Lin JZY Biotech Inc. (effective July 20, 2020)
     • Licensed technology used in the company’s products.
     • Territory: Worldwide excluding China.
     • Term: For the term of the underlying patent; expires January 11, 2035.
     • Consideration: $10.00.
     • Related party: Shang Liu, President/CEO and director, controls JZY Biotech.

Financial position (as of December 31, 2025)

• Cash and cash equivalents: $26,775
• Total assets: $26,775
• Total liabilities: $379,833
• Total stockholders’ equity: $(343,713)
• Liabilities exceed assets and stockholders’ equity is negative.

Employees and governance

• Officers: Three individuals serve as non-employee officers.
• Board and governance: The company provides no description of board expertise in enterprise risk management or technology. Cybersecurity risk management processes are not implemented.

Properties and operations

• Principal address: 7316 Capilano Dr., Solon, Ohio 44139
• The company reports no real estate or other physical property ownership. Officers and directors work remotely.

Regulatory, legal, and risk disclosures

• The company reports it is not aware of regulatory approvals required for its products or services and that it is not subject to regulations related to ownership or licensing of intellectual property.
• The company reports no pending legal proceedings.
• No formal processes are described for assessing or managing cybersecurity risks; the board lacks stated experience in enterprise risk management or technology.

Competitive landscape

• The company identifies competition from traditional offline resources and online providers for consumer listings, ratings, and referrals. Competitive factors include brand strength, content reliability, and the breadth and depth of information.